Serodus AS (Serodus) today announced it has entered into a license agreement with Roche (SIX: RO) (SIX: ROG) (OTCQX: RHHBY) for a selective serotonin-4 (5-HT 4) antagonist for the potential treatment of (RO1160367).Serodus will use its proprietary knowledge to optimize and develop the compound as the SER101 to establish clinical proof of concept for the indication of heart failure, addressing a market of over $ 5 billion a year.
Steiness Eve, MD, CEO of Serodus, said: ‘We are excited about this excellent opportunity to work with Roche compound. Serodus This agreement to move the program directly in the heart failure clinic to wait for our preclinical development.’
The effect of 5-HT 4 antagonists in heart failure has been demonstrated in rats and humans and remains an important area for research and development of appropriate treatments.
Researchers at the University of Oslo (Prof. Levy and colleagues) have discovered the presence of 5-HT 4 receptors on muscle cells in failing cardiac ventricles and heart failure ventricle expresses 5-HT4 receptor in response to serious conditions.
Serodus, a biopharmaceutical company committed to developing innovative compounds for cardiovascular disease, Norway, has been authorized RO1160367, a drug candidate ready to enter into a clinical trial phase II proof-of-concept study in heart failure.